Psyence Biomedical Welcomes Results Of A Recent Study Highlighting Benefits Of Nature Derived Psilocybin Vs. Synthetic Psilocybin
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomedical Ltd. (NASDAQ:PBM) welcomed a study published in Molecular Psychiatry, showing nature-derived psilocybin may be more therapeutic than synthetic versions, particularly in neuroplasticity effects. The study, not funded by Psyence Biomed, was conducted by Hebrew University. Psyence Biomed, focusing on nature-derived psilocybin for Palliative Care, is preparing for a Phase llb clinical trial targeting Adjustment Disorder in cancer patients. The U.S. Palliative Care market is expected to grow to $28.6 billion by 2030. Psyence Biomed's approach could potentially improve patient quality of life and reduce healthcare costs.
March 18, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Psyence Biomedical Ltd. (NASDAQ:PBM) is positively highlighted for its focus on nature-derived psilocybin, with a study suggesting its superior therapeutic benefits over synthetic versions. The company is moving towards a Phase llb clinical trial for treating Adjustment Disorder in Palliative Care, with a significant market growth projection for Palliative Care.
The positive outcome of the study on nature-derived psilocybin, combined with Psyence Biomed's unique position in researching this for Palliative Care, suggests a potential uplift in investor confidence and stock performance. The anticipation of the Phase llb clinical trial and the projected growth of the Palliative Care market further support a positive short-term impact on PBM's stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100